个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共28条记录   A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma [作者：Harrison, SJ; Quach, H; Link, E; Seymour, JF; Ritchie, DS; Ruell, S; Dean, J; Januszewicz, H; Johnstone, R; Neeson, P; Dickinson, M; Nichols, J; Prince, HM,期刊：Blood, 页码：6274-6283 , 文章类型： Article，,卷期：2011年118-24] We report results from a study exploring the combination of romidepsin, bortezomib, and dexamethasone for the treatment of patients with multiple myeloma (MM) previously treated with > 1 prior therapy. The primary object... Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study [作者：Lindqvist, EK; Goldin, LR; Landgren, O; Blimark, C; Mellqvist, UH; Turesson, I; Wahlin, A; Bjorkholm, M; Kristinsson, SY,期刊：Blood, 页码：6284-6291 , 文章类型： Article，,卷期：2011年118-24] The associations between immune-related conditions and multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) have previously been investigated with inconsistent results. In a large populatio... Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma [作者：Boll, B; Bredenfeld, H; Gorgen, H; Halbsguth, T; Eich, HT; Soekler, M; Markova, J; Keller, U; Graeven, U; Kremers, S; Geissler, M; Trenn, G; Fuchs, M; von Tresckow, B; Eichenauer, DA; Borchmann, P; Engert, A,期刊：Blood, 页码：6292-6298 , 文章类型： Article，,卷期：2011年118-24] Approximately 20% of all Hodgkin lymphoma (HL) patients are older than 60 years and have a poor prognosis, mainly because of increased treatment-related toxicity resulting in reduced overall dose intensity and more treat... A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis [作者：Cuker, A; Coles, AJ; Sullivan, H; Fox, E; Goldberg, M; Oyuela, P; Purvis, A; Beardsley, DS; Margolin, DH,期刊：Blood, 页码：6299-6305 , 文章类型： Article，,卷期：2011年118-24] In a phase 2 clinical trial of annual alemtuzumab for treatment of relapsing-remitting multiple sclerosis, 6 of 216 patients (2.8%) developed immune thrombocytopenia (ITP). Over mean follow-up of 4.5 years, the incidence... Safety of long-term treatment of HAM/TSP patients with valproic acid [作者：Olindo, S; Belrose, G; Gillet, N; Rodriguez, S; Boxus, M; Verlaeten, O; Asquith, B; Bangham, C; Signate, A; Smadja, D; Lezin, A; Cesaire, R; Willems, L,期刊：Blood, 页码：6306-6309 , 文章类型： Article，,卷期：2011年118-24] HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a neurodegenerative disease of the central nervous system induced by human T-lymphotropic virus type 1. As a potential therapeutic approach, we previou... Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia [作者：Bluteau, D; Gilles, L; Hilpert, M; Antony-Debre, I; James, C; Debili, N; Camara-Clayette, V; Wagner-Ballon, O; Cordette-Lagarde, V; Robert, T; Ripoche, H; Gonin, P; Swierczek, S; Prchal, J; Vainchenker, W; Favier, R; Raslova, H,期刊：Blood, 页码：6310-6320 , 文章类型： Article，,卷期：2011年118-24] RUNX1 encodes a DNA-binding alpha subunit of the core-binding factor, a heterodimeric transcription factor. RUNX1 is a master regulatory gene in hematopoiesis and its disruption is one of the most common aberrations in a... CD19-independent instruction of murine marginal zone B-cell development by constitutive Notch2 signaling [作者：Hampel, F; Ehrenberg, S; Hojer, C; Draeseke, A; Marschall-Schroter, G; Kuhn, R; Mack, B; Gires, O; Vahl, CJ; Schmidt-Supprian, M; Strobl, LJ; Zimber-Strobl, U,期刊：Blood, 页码：6321-6331 , 文章类型： Article，,卷期：2011年118-24] B cell-specific gene ablation of Notch2 results in the loss of the marginal zone (MZ) B-cell lineage. To analyze the effects of constitutive Notch2 signaling in B cells, we have generated a transgenic mouse strain that a... FcRL4 acts as an adaptive to innate molecular switch dampening BCR signaling and enhancing TLR signaling [作者：Sohn, HW; Krueger, PD; Davis, RS; Pierce, SK,期刊：Blood, 页码：6332-6341 , 文章类型： Article，,卷期：2011年118-24] Fc receptor-like 4 (FcRL4) is expressed on the surface of a subset of memory B cells (MBCs) located at sites of invading pathogens in mucosal lymphoid tissues in healthy individuals. Recently, FcRL4(+) MBCs were shown to... TGF-beta 1 signaling and Kruppel-like factor 10 regulate bone marrow-derived proangiogenic cell differentiation, function, and neovascularization [作者：Wara, AK; Foo, SY; Croce, K; Sun, XH; Icli, B; Tesmenitsky, Y; Esen, F; Lee, JS; Subramaniam, M; Spelsberg, TC; Lev, EI; Leshem-Lev, D; Pande, RL; Creager, MA; Rosenzweig, A; Feinberg, MW,期刊：Blood, 页码：6450-6460 , 文章类型： Article，,卷期：2011年118-24] Emerging evidence demonstrates that proangiogenic cells (PACs) originate from the BM and are capable of being recruited to sites of ischemic injury where they contribute to neovascularization. We previously determined th... Bone marrow-derived CMPs and GMPs represent highly functional proangiogenic cells: implications for ischemic cardiovascular disease [作者：Wara, AK; Croce, K; Foo, SY; Sun, XH; Icli, B; Tesmenitsky, Y; Esen, F; Rosenzweig, A; Feinberg, MW,期刊：Blood, 页码：6461-6464 , 文章类型： Article，,卷期：2011年118-24] Clinical studies using bone marrow-derived proangiogenic cells (PACs) have demonstrated modest improvements of function and/or perfusion of ischemic myocardium or skeletal muscle. Because the identities of these PACs and... SYK inhibition and response prediction in diffuse large B-cell lymphoma [作者：Cheng, SH; Coffey, G; Zhang, XHN; Shaknovich, R; Song, ZB; Lu, P; Pandey, A; Melnick, AM; Sinha, U; Wang, YL,期刊：Blood, 页码：6342-6352 , 文章类型： Article，,卷期：2011年118-24] Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, and the role of SYK in its pathogenesis is not completely understood. Using tissue microarray, we demonstrated for the first time tha... The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia [作者：Morabito, F; De Filippi, R; Laurenti, L; Zirlik, K; Recchia, AG; Gentile, M; Morelli, E; Vigna, E; Gigliotti, V; Calemma, R; Amoroso, B; Neri, A; Cutrona, G; Ferrarini, M; Molica, S; Del Poeta, G; Tripodo, C; Pinto, A,期刊：Blood, 页码：6353-6361 , 文章类型： Article，,卷期：2011年118-24] Identification of patients at risk of early disease progression is the mainstay of tailored management in chronic lymphocytic leukemia (CLL). Although application of established biomarkers is limited by intrinsic detecti... Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia [作者：Kuhnl, A; Gokbuget, N; Kaiser, M; Schlee, C; Stroux, A; Burmeister, T; Mochmann, LH; Hoelzer, D; Hofmann, WK; Thiel, E; Baldus, CD,期刊：Blood, 页码：6362-6367 , 文章类型： Article，,卷期：2011年118-24] Aberrant activation of the Wnt pathway plays a pathogenetic role in various tumors and has been associated with adverse outcome in acute lymphoblastic leukemia (ALL). LEF1, a key mediator of Wnt signaling, has been linke... Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors [作者：Neri, P; Ren, L; Gratton, K; Stebner, E; Johnson, J; Klimowicz, A; Duggan, P; Tassone, P; Mansoor, A; Stewart, DA; Lonial, S; Boise, LH; Bahlis, NJ,期刊：Blood, 页码：6368-6379 , 文章类型： Article，,卷期：2011年118-24] Chromosomal instability is a defining feature of clonal myeloma plasma cells that results in the perpetual accumulation of genomic aberrations. In addition to its role in protein homeostasis, the ubiquitin-proteasome sys... Endogenous Bcl-x(L) is essential for Myc-driven lymphomagenesis in mice [作者：Kelly, PN; Grabow, S; Delbridge, ARD; Strasser, A; Adams, JM,期刊：Blood, 页码：6380-6386 , 文章类型： Article，,卷期：2011年118-24] Impaired apoptosis is a cancer hallmark, and some types of lymphomas and other cancers harbor mutations that directly affect key cell death regulators, such as Bcl-2 family members. However, because the majority of tumor... IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect [作者：Benson, DM; Bakan, CE; Zhang, SH; Collins, SM; Liang, J; Srivastava, S; Hofmeister, CC; Efebera, Y; Andre, P; Romagne, F; Blery, M; Bonnafous, C; Zhang, JY; Clever, D; Caligiuri, MA; Farag, SS,期刊：Blood, 页码：6387-6391 , 文章类型： Article，,卷期：2011年118-24] Multiple myeloma (MM) patients who receive killer cell Ig-like receptor (KIR) ligand-mismatched, T cell-depleted, allogeneic transplantation may have a reduced risk of relapse compared with patients who receive KIR ligan...